| Schedule of operating segments |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended June 30, 2025: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | Cost of revenues | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 1,523,099 | | | 3,332 | | | 1,526,431 | | | 27,819 | | | 122,764 | | | - | | | 1,677,014 | General and administrative | | | - | | | - | | | - | | | - | | | 1,014,468 | | | 72,397 | | | 1,086,865 | Adjusted loss from operations | | | (1,523,099) | | | (3,332) | | | (1,526,431) | | | (27,819) | | | (1,137,232) | | | (72,397) | | | (2,763,879) | Share-based compensation | | | 26,487 | | | 839 | | | 27,326 | | | (27,326) | | | 72,187 | | | (72,187) | | | - | Depreciation and amortization | | | 423 | | | 70 | | | 493 | | | (493) | | | 210 | | | (210) | | | - | Loss from operations | | | (1,550,009) | | | (4,241) | | | (1,554,250) | | | - | | | (1,209,629) | | | - | | | (2,763,879) | Other (expenses) income, net | | | - | | | - | | | - | | | - | | | 61,903 | | | - | | | 61,903 | Net loss before income taxes | | $ | (1,550,009) | | $ | (4,241) | | $ | (1,554,250) | | $ | - | | $ | (1,147,726) | | $ | - | | $ | (2,701,976) |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the three months ended June 30, 2024: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | 2,342 | | $ | - | | $ | 2,342 | | $ | - | | $ | - | | $ | - | | $ | 2,342 | Cost of revenues | | | (2,342) | | | - | | | (2,342) | | | - | | | - | | | - | | | (2,342) | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 261,313 | | | 61,276 | | | 322,589 | | | 22,669 | | | 155,900 | | | - | | | 501,158 | General and administrative | | | - | | | - | | | - | | | - | | | 1,206,923 | | | 36,594 | | | 1,243,517 | Adjusted loss from operations | | | (261,313) | | | (61,276) | | | (322,589) | | | (22,669) | | | (1,362,823) | | | (36,594) | | | (1,744,675) | Share-based compensation | | | 20,940 | | | 617 | | | 21,557 | | | (21,557) | | | 36,118 | | | (36,118) | | | - | Depreciation and amortization | | | 953 | | | 159 | | | 1,112 | | | (1,112) | | | 476 | | | (476) | | | - | Loss from operations | | | (283,206) | | | (62,052) | | | (345,258) | | | - | | | (1,399,417) | | | - | | | (1,744,675) | Other (expenses) income, net | | | (31,346) | | | - | | | (31,346) | | | - | | | 131,519 | | | - | | | 100,173 | Net loss before income taxes | | $ | (314,552) | | $ | (62,052) | | $ | (376,604) | | $ | - | | $ | (1,267,898) | | $ | - | | $ | (1,644,502) |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the six months ended June 30, 2025: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | | $ | - | Cost of revenues | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 3,273,701 | | | 61,667 | | | 3,335,368 | | | 55,572 | | | 227,754 | | | - | | | 3,618,694 | General and administrative | | | - | | | - | | | - | | | - | | | 2,062,842 | | | 108,851 | | | 2,171,693 | Adjusted loss from operations | | | (3,273,701) | | | (61,667) | | | (3,335,368) | | | (55,572) | | | (2,290,596) | | | (108,851) | | | (5,790,387) | Share-based compensation | | | 52,975 | | | 1,679 | | | 54,654 | | | (54,654) | | | 108,458 | | | (108,458) | | | - | Depreciation and amortization | | | 787 | | | 131 | | | 918 | | | (918) | | | 393 | | | (393) | | | - | Loss from operations | | | (3,327,463) | | | (63,477) | | | (3,390,940) | | | - | | | (2,399,447) | | | - | | | (5,790,387) | Other (expenses) income, net | | | - | | | - | | | - | | | - | | | 137,143 | | | - | | | 137,143 | Net loss before income taxes | | $ | (3,327,463) | | $ | (63,477) | | $ | (3,390,940) | | $ | - | | $ | (2,262,304) | | $ | - | | $ | (5,653,244) |
The following table presents the revenues, significant expenses, and operating results of the Company's reportable segments for the six months ended June 30, 2024: | | | | | | | | | | | | | | | | | | | | | | | | Specialized
BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Adjustments | | Corporate | | Adjustments | | Consolidated | Revenues | | $ | 119,371 | | $ | - | | $ | 119,371 | | $ | - | | $ | - | | $ | - | | $ | 119,371 | Cost of revenues | | | (119,371) | | | - | | | (119,371) | | | - | | | - | | | - | | | (119,371) | Gross profit | | | - | | | - | | | - | | | - | | | - | | | - | | | - | Significant expenses: | | | | | | | | | | | | | | | | | | | | | | Research and development | | | 1,100,292 | | | 106,526 | | | 1,206,818 | | | 45,041 | | | 344,339 | | | - | | | 1,596,198 | General and administrative | | | - | | | - | | | - | | | - | | | 2,189,797 | | | 75,771 | | | 2,265,568 | Adjusted loss from operations | | | (1,100,292) | | | (106,526) | | | (1,206,818) | | | (45,041) | | | (2,534,136) | | | (75,771) | | | (3,861,766) | Share-based compensation | | | 41,612 | | | 1,205 | | | 42,817 | | | (42,817) | | | 74,819 | | | (74,819) | | | - | Depreciation and amortization | | | 1,906 | | | 318 | | | 2,224 | | | (2,224) | | | 952 | | | (952) | | | - | Loss from operations | | | (1,143,810) | | | (108,049) | | | (1,251,859) | | | - | | | (2,609,907) | | | - | | | (3,861,766) | Other (expenses) income, net | | | (23,806) | | | - | | | (23,806) | | | - | | | 325,743 | | | - | | | 301,937 | Net loss before income taxes | | $ | (1,167,616) | | $ | (108,049) | | $ | (1,275,665) | | $ | - | | $ | (2,284,164) | | $ | - | | $ | (3,559,829) |
The following table provides a reconciliation of total segment loss to consolidated loss before income taxes for the three months ended June 30: | | | | | | | | | 2025 | | 2024 | Loss from operations - reportable segments | | $ | (1,554,250) | | $ | (345,258) | Loss from operations - corporate | | | (1,209,629) | | | (1,399,417) | Interest income (expense), net | | | 69,823 | | | 35,925 | Other income (expense), net | | | (7,920) | | | 64,248 | Net loss before income taxes | | $ | (2,701,976) | | $ | (1,644,502) |
The following table provides a reconciliation of total segment loss to consolidated loss before income taxes for the six months ended June 30: | | | | | | | | | 2025 | | 2024 | Loss from operations - reportable segments | | $ | (3,390,940) | | $ | (1,251,859) | Loss from operations - corporate | | | (2,399,447) | | | (2,609,907) | Interest income (expense), net | | | 145,851 | | | 64,767 | Other income (expense), net | | | (8,708) | | | 237,170 | Net loss before income taxes | | $ | (5,653,244) | | $ | (3,559,829) |
Segment Assets The Company’s total assets by segment as of June 30, 2025, are presented below: | | | | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health
Solutions | | Total
Segments | | Corporate | | Consolidated | Total assets | | $ | 112,342 | | $ | 2,705 | | $ | 115,047 | | $ | 5,645,600 | | $ | 5,760,647 |
The Company’s total assets by segment as of June 30, 2024, are presented below: | | | | | | | | | | | | | | | | | | Specialized BioTherapeutics | | Public Health Solutions | | Total
Segments | | Corporate | | Consolidated | Total assets | | $ | 183,858 | | $ | 2,917 | | $ | 186,775 | | $ | 9,678,304 | | $ | 9,865,079 |
|